Big Partnership coming soon
REASONS TO INVEST IN STEM CELL THERAPEUTICS
• Lead program adressing a major unmet need with a large commercial potential
- Stroke is the leading cause of serious, long-term disability 1
- On average, a stroke occurs every 40 seconds 1
- Only treatments available: tPA (<4% of ischemic patients treated) and aspirin
• Current lack of effective treatment for reducing and repairing damage caused by stroke
• Shortened path to regulatory approval, decreased development risk and cost due to current FDA approval status of the drugs used in NTx®-265
• Attractive therapeutic window of NTx®-265 (within 24-48hours post stroke) and easy administration method (avoid the need for invasive brain surgery)
• Encouraging results from BETAS Phase IIa stroke trial demonstrated positive drug related effects on visual, motor and cognitive recovery in patients who suffered acute ischemic stroke.
• Additional indications being explored, traumatic brain injury (TBI) and multiple sclerosis (MS); also representing major unmet needs and large commercial potential
• Clinical programs with strong partnering potential
• Issued and pending patents protecting SCT's extensive intellectual property portfolio
AI
Market Data 
Markets 
